SCANIS RECEIVES EUROPEAN PATENT
FOR MAMMOGRAPHY FILM ANALYSIS TECHNOLOGY

FOSTER CITY, Calif., December 14, 2006 SCANIS, Inc. an image analysis software company has received a patent from the European Patent Office for the technology underlying the Company's MAMMEX(tm) Mammography Computer-Aided-Diagnosis System. The European Union patent number 0502027 is for a Computer-Based Method for Assisting an Investigation of a Human Breast for a Malignancy. Similar patents have been previously issued in the US, Japan and Canada. "This patent extends our marketing outreach for the MAMMEX product line beyond the United States, Japan and Canada," according to Robert Chapman, SCANIS Chairman and CEO. "As a result, specific European country patents are being issued in the United Kingdom, Germany, France and Italy," he said. The MAMMEX is intended to help radiologists improve the accuracy of evaluating mammograms in the battle against breast cancer. It is also available for mammography research and education. The technology identifies suspicious abnormalities and displays them on a video monitor with printout capabilities for comparison with a radiologist's reading of a mammogram film.

(Caution: Investigational device limited by United States law to investigational use only.)

About SCANIS, Inc.
SCANIS, Inc. provides computer-assisted detection systems to aid radiologists in more reliable screening for potential breast cancers in order to improve patient outcomes and quality of life and for economic benefits in healthcare. Its SemiScan subsidiary develops machine vision software for improving yield and economics in manufacturing, especially in the semiconductor industry. Further information can be viewed at the company's web site www.scanis.com.

Certain statements contained in this News Release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from such forward-looking statements. Such risks include, but are not limited to, uncertainties associated with litigation and/or government regulation, changes in Medicare reimbursement policies, competitive factors, and other risks that are detailed in the Companies’ periodic filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely” and similar expressions identify forward-looking statements. Readers are cautioned to avoid placing undue reliance on such forward-looking statements, which speak only as of the date the statements were made.